文献速递肝病

VCTE肝硬度下降30%识别MASH组织学改善的临床效用

Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.
PubMed 文献 · Hepatology · 2026-09-02

本研究基于160例活检证实MASH伴2-3期纤维化患者的前瞻性数据,评估VCTE肝硬度相对下降≥30%与纤维化逆转的关联。主要队列AUC为0.68(95%CI 0.58-0.77),校正后OR为4.23(95%CI 1.79-10.38,p=0.001);验证队列(n=48)AUC为0.62(95%CI 0.48-0.76)。结论为VCTE肝硬度下降30%检测纤维化逆转的准确性中等,仍需更有效的生物标志物。

要点

  • VCTE肝硬度相对下降≥30%与MASH纤维化逆转独立相关(校正OR 4.23)。
  • 该指标检测纤维化逆转的准确性中等,主要队列AUC为0.68。
  • 验证队列AUC为0.62,提示需更有效的治疗反应生物标志物。

核心结论

  • VCTE肝硬度相对下降≥30%检测MASH纤维化逆转且不伴MASH恶化的准确性中等,仍需更有效的生物标志物。

研究设计与样本

  • 前瞻性研究,纳入160例活检证实MASH伴2-3期纤维化的成人(64%女性),来自一项随机、2b期、多中心、安慰剂对照的pegozafermin试验。
  • 所有参与者在2个时间点接受同期VCTE评估和肝活检,主要终点为纤维化逆转且不伴MASH恶化。
  • 另设来自美国和新加坡的验证队列(n=48)。

主要发现

  • 主要队列中VCTE肝硬度相对下降≥30%检测纤维化逆转的AUC为0.68(95%CI 0.58-0.77)。
  • 校正年龄、性别、2型糖尿病、BMI和种族后,VCTE肝硬度相对下降≥30%与纤维化逆转独立相关(校正OR 4.23,95%CI 1.79-10.38,p=0.001)。
  • 验证队列中VCTE肝硬度下降≥30%检测纤维化逆转的AUC为0.62(95%CI 0.48-0.76)。

关键数值与推荐

  • 主要队列中VCTE肝硬度相对下降≥30%检测纤维化逆转的AUC为0.68(95%CI 0.58-0.77)。
  • 验证队列中VCTE肝硬度下降≥30%检测纤维化逆转的AUC为0.62(95%CI 0.48-0.76)。
  • 校正后OR为4.23(95%CI 1.79-10.38,p=0.001)。

临床怎么用

  • VCTE肝硬度相对下降≥30%可作为MASH治疗反应的无创参考指标,但准确性中等,不宜单独作为决策依据。
  • 临床解读该指标时应结合活检或其他生物标志物综合评估。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The American Association for the Study of Liver Diseases (AASLD) recommends that a decline in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) can be used as a non-invasive endpoint for treatment response in metabolic dysfunction-associated steatohepatitis (MASH), but there are limited data supporting this statement. We examined the association between a ≥30% relative decline in LSM and fibrosis regression. APPROACH AND RESULTS: This prospective study included 160 adults (64% female) with biopsy-proven MASH and stage 2-3 fibrosis from a randomized, phase 2b, multicenter, placebo-controlled trial of the fibroblast growth factor 21 analog pegozafermin. All participants underwent contemporaneous VCTE assessments and liver biopsy at 2 time points. The primary endpoint was fibrosis regression without worsening MASH. The median (IQR) age and body mass index of participants were 56.0 (49.0-62.0) years and 36.5 (32.2-40.4) kg/m 2 . The area under the receiver operating curve (AUC) of a ≥30% relative decline in LSM by VCTE for detecting fibrosis regression was 0.68 (95% CI 0.58-0.77). In multivariable analyses adjusted for age, sex, type 2 diabetes, BMI, and ethnicity, a ≥30% relative decline in LSM was independently associated with fibrosis regression (adjusted OR 4.23, 95% CI 1.79-10.38, p =0.001). In a distinct validation cohort (n=48) from the United States and Singapore, a ≥30% decline in LSM for detecting fibrosis regression yielded an AUC of 0.62 (95% CI 0.48-0.76). CONCLUSION: A ≥30% relative decline in LSM by VCTE had modest accuracy to detect fibrosis regression without worsening MASH. More effective biomarkers for treatment response are required.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Loomba R, Chen R, Wang Y, et al. Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH. Hepatology. 2026. PMID: 42691332. doi:10.1097/HEP.0000000000001856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。